Sun Pharmaceutical Industries said that it has entered into an agreement for the acquisition of all the outstanding shares of Checkpoint Therapeutics, Inc., an immunotherapy and targeted oncology ...

Sun Pharmaceutical announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, an immunotherapy and oncology company.

The FDA’s Oncologic Drugs Advisory Committee recently voted to narrow the label for checkpoint inhibitors Keytruda and Opdivo in stomach and esophageal cancers based on PD-L1 expression levels—but the ...

The upfront cash payment of $4.10 per share of common stock represents a premium of around 66% to Checkpoint’s closing share ...

Sun Pharma to acquire Checkpoint Therapeutics, expanding innovative portfolio in onco-derm therapy with FDA-approved UNLOXCYT ...

Sun Pharmaceuticals announced that it will acquire Checkpoint Therapeutics, a company specializing in immunotherapy and ...

Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its ...

Sun Pharmaceuticals will acquire Checkpoint Therapeutics for $355 million, bringing the FDA-approved anti-PD-L1 treatment for ...

Sun Pharmaceutical Industries Ltd. on Monday announced it will acquire US-based cancer treatment provider Checkpoint ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.